← All trials
NCT01632241
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 19, 2013
- Primary completion
- Aug 2, 2018
- Completion date
- Feb 14, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 501
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Human Genome SciencesLead sponsor
- GlaxoSmithKlineStudy director
- GlaxoSmithKlineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.